Aethlon Medical Files 8-K on Security Holder Rights

TL;DR

AETH filed an 8-K, changes to shareholder rights and bylaws. Check it out.

AI Summary

Aethlon Medical, Inc. filed an 8-K on October 16, 2025, reporting material modifications to the rights of security holders and amendments to its articles of incorporation or bylaws. The filing also includes financial statements and exhibits. The company is incorporated in Nevada and its principal executive offices are located in San Diego, California.

Why It Matters

This 8-K filing indicates potential changes affecting Aethlon Medical's shareholders and corporate structure, requiring investor attention.

Risk Assessment

Risk Level: medium — Filings related to modifications of security holder rights and amendments to corporate documents can introduce uncertainty and potential risks for investors.

Key Players & Entities

• Aethlon Medical, Inc. (company) — Registrant
• Nevada (jurisdiction) — State of incorporation
• San Diego, California (location) — Principal executive offices
• October 16, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share AEMD The Nasdaq

Filing Documents

• aemd_8k.htm (8-K) — 35KB
• aemd_ex0301.htm (EX-3.1) — 3KB
• image_001.jpg (GRAPHIC) — 205KB
• 0001683168-25-007586.txt ( ) — 488KB
• aemd-20251016.xsd (EX-101.SCH) — 3KB
• aemd-20251016_lab.xml (EX-101.LAB) — 33KB
• aemd-20251016_pre.xml (EX-101.PRE) — 22KB
• aemd_8k_htm.xml (XML) — 4KB

03 Material Modification to Rights of Security

Item 3.03 Material Modification to Rights of Security Holders. On October 14, 2025, Aethlon Medical, Inc., a Nevada corporation (the "Company"), filed a Certificate of Change (the "Certificate of Change") pursuant to Section 78.209 of the Nevada Revised Statutes ("NRS") with the Secretary of State of the State of Nevada authorizing a 1-for-10 reverse stock split (the "Reverse Stock Split") of the Company's issued and outstanding shares of common stock, $0.001 par value per share (the "Common Stock"). The Reverse Stock Split will become effective on the Effective Date (as defined below). Reason for the Reverse Stock Split The Company is effectuating the Reverse Stock Split as a part of the Company's overall capital-markets and operating plan, including but not limited dilution management and continued compliance with Nasdaq Listing Rule 5550(a)(2). Effects of the Reverse Stock Split Effective Date; Symbol; CUSIP Number. The Reverse Stock Split will become effective as of 10:00 am. Eastern Time on October 16, 2025 (the "Effective Date"). It is expected that the Common Stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market when the market opens on October 20, 2025, under the existing trading symbol "AEMD". The CUSIP number for the Common Stock will change to 00808Y604. Split Adjustment; No Fractional Shares . On the Effective Date, the total number of shares of the Company's Common Stock held by each stockholder will be automatically converted into the number of whole shares of Common Stock equal to (i) the number of issued and outstanding shares of Common Stock held by such stockholder immediately prior to the Reverse Stock Split, divided by (ii) ten (10). No fractional shares will be issued, and no cash or other consideration will be paid. Instead, the Company will issue one whole share of the post-Reverse Stock Split Common Stock to any stockholder who otherwise would have received a fractional share as a result of the Reverse Stock

03 Amendments to Articles of Incorporation or Bylaws;

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. The information set forth in Item 3.03 of this Current Report on Form 8-K is incorporated by reference into this Item 5.03. A copy of the Certificate of Change is filed as Exhibit 3.1 to this Current Report on Form 8-K.

01 Financial

Item 9.01 Financial (d) Exhibits Exhibit Number Description 3.1 Certificate of Change 104 Cover Page Interactive Data File (embedded within the inline XBRL Document) 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 16, 2025 Aethlon Medical, Inc. By: /s/ James B. Frakes Name: James B. Frakes Chief Executive Officer and Chief Financial Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR